Pharmacological Properties of Loop Diuretics and Their Clinical Effects

Edematous states caused by an excessesive extracellular fluid retention are major components of cardiovascular and renal disorders including chronic kidney disease, nephrotic syndrome, and heart failure. The use of diuretic drugs from various groups including loop duiretics are important means of pharmacological correction of these clinical conditions. Moreover, diuretics used to lower bood pressure as a part of antihypertensive treatment, reduce cardiovascular events. The response of patients to the dose of a diuretic is reflected by a sigmoid dose-response curve which can be affected by changes of sodium content in the body. Loop diuretics may fail to control salt and water retention despite the use of appropriate doses. The main reasons for loop diuretic resistance may be determined by further reduction of glomerular filtration rate and reduced peak concentration of loop diuretics in primary urine. Chronic treatment with loop diuretics can cause compensatory hyperthrophy of epithelial cells along the ascending limb of the loop of Henle and thus decrease of its diuretic effect. The principles of avoiding this phenomenon are the restriction of sodium intake, correction of doses, timing and frequency of drug administration, and use of combination diuretic therapy. Loop diuretic - related adverse events that involve uricaemia and ototoxicity also should be taken into consideration.

петлевые диуретики, устойчивость к диуретикам, кривая зависимости доза-ответ, хроническая почечная болезнь, нефротический синдром, loop diuretics, diuretic resistance, dose-response curve, chronic kidney disease, nephrotic syndrome

1. Ernst M. E., Gordon J. A. Diuretic therapy: key aspects in hypertension and renal diseases. J. Nephrol 2010; 23 (5): 487-493.

2. Ernst M. E., Mann S.J. Diuretics in the Treatment of Hypertension. Semin Nephrol 2011; 31 (11): 495-502.

3. Sica D. A., Carter B., Cushman W., Hamm L. Thiazide and loop diuretics. J. Clin Hypertens 2011; 13 (9): 639-643.

4. Leto L., Aspromonte N., Feola M. Efficacy and safety of loop diuretic therapy in acute decompensated heart failure: a clinical review. Heart Fail Rev 2014; 19 (2): 237-246.

5. Chiong J. R., Cheung R.J. Loop Diuretic Therapy in Heart Failure: The need for Solid Evidence on a Fluid Issue. Clin Cardiol 2010; 33 (6): 345-352.

6. Sica D. A. Diuretic use in renal disease. Nat Rev Nephrol 2011; 8 (2): 100-109.

7. Cox Z. L., Lenihan D.J. Loop Diuretic Resistance in Heart Failure: Resistance Etiology Based Strategies to Restoring Diuretic Efficacy. J. Cardiac Fail 2014; 20: 611-622.

8. Преображенский Д. В., Некрасова Н. И., Хосева Е.Н. и др. Торасемид - эффективный петлевой диуретик для длительной терапии артериальной гипертензии. Кардиология 2011; 4: 67-73.

9. Евдокимова А. Г., Коваленко Е. В., Евдокимов В. В., Ложкина М.В. Возможности применения торасемида в клинической практике. Кардиология 2011; 4: 67-73

10. Felker G. M., Menz R.J. Acute Decompensated Heart Failure. JACC 2012; 59 (24): 2145-2153.

11. Buggey J., Mentz R. J., Pitt B. et al. A reappraisal of loop diuretic choice in heart failure patients. Am Heart J. 2015; 169: 323-333.

12. Felker G. M., Menz R.J., Shankar S. S., Brater D. K. Loop diuretics: from the Na-K-2Cl transporter to clinical use. Am J. Physiol Renal Physiol 2003; 284: F11 - F21.

13. Roush G. S., Kaur R., Ernst M. E. Diuretics: A Rewiew and Update. J. Cardiovasc Pharmacol Ther 2014; 19 (1): 5-13.

14. Subramanya A. R., Elisson D. H. Diuretic Therapy. In: Core Concepts in the Disorders of Fluid, Electrolytes and Acid-Base Balance 2013; 171-201.

15. Wilcox C. S. New Insights into Diuretic Use in patients with Chronic Renal Disease. J. Am Soc Nephrol 2002; 13: 798-805.

16. Felker G. M. Diuretic management in Heart failure. Congest Heart Fail 2010; 16 (4): S68 - S72.

17. De Bruyne L. K. M. Mechanism and management of diuretic resistance in congestive heart failure. Postgrad Med J. 2003; 79: 268-271.

18. Felker G. M. Loop diuretics in heart failure. Heart Fail Rev 2012; 17: 305-311.

19. Buerkert J., Martin D., Prasad J. et al. Response of deep nephrons and the terminal collecting duct to a reduction in renal mass. Am J. Physiol 1979; 236: F454-F464.

20. Dargie H. J., Allison M. E., Kennedy A. C., Gray M. J. High dosage metolazone in chronic renal failure. Br Med J. 1972; 4: 196-198.

21. Lowenthal D. T., Dickermann D. The use of diuretics in varying degrees of renal impairment: An overview. Clin Exp Hypertens 1983; A5: 297-307.

22. Koomans H. A., Roos J. C., Boer P. et al. Salt sensitivity of blood pressure in chronic renal failure: evidence for renal control of body fluid distribution in man. Hypertension 1982; 4: 190-197.

23. Wollam G. L., Tarazi R. C., Bravo E. L., Dustan H. P. Diuretic potency of combined hydrochlorothiazide and furosemide therapy in patients with azotemia. Am J. Med 1982; 72: 929-938.

24. Brunner G., Von Bergmann K., Häcker W., Von Möllendorf E. Comparison of diuretic effects and pharmacokineticks of toresamide and furosemide after a single oral dose in patients with hydropically decompensated cirrhosis of the liver. Arzneim-Forsh Drug Res 1998; 38: 176-179.

25. Pichette V., du Souich P. Role of kidneys inb the metabolism of furosemide: its inhibition by probenicid. J. Am Soc Nephrol 1996; 7: 345-349.

26. Humes H. D. Insights into ototoxicity. Analogies to nephrotoxicity. Ann NY Acad Sci 1999; 884: 15-18.

27. Shankar S. S., Brater C. D. Loop diuretics: from the Na-K-2Cl transporter to clinical use. Am J Physiol Renal Physiol 2003; 284: F11-F21.

28. Jutabha P., Anzai N., Wempe M. F. et al. Apical voltage - driven urate efflux transporter NPT4 in renal proximal tubule. Nucleosides, Nucleotides and Nucleic Acids 2010; 30: 1302-1311.

29. Rahman M., Pressel S., Davis B. R. et al. Cardiovascular outcomes in high-risk hypertensive patiens stratified by baseline glomerular filtration rate. Ann Intern Med 2006; 144: 172-180.

30. Calhoun D. A., Jones D., Textor S. et al. Resistant hypertension: diagnosis, evaluation, and treatment. A scientific statement from the American Heart Association professional Education Committee of the Council for High Blood Pressure Research. Hypertension 2008; 54: 1403-1419.

31. Sica D. A. The risks and benefits of aldosterone antagonists. Curr Heart Fail Rep 2005; 2: 65-71.

32. Powers D. A., Duggan J., Brady H. R. Renal-dose (low-dose) dopamine for treatment of sepsis-related and other forms of acute renal failure: ineffecxtive and probably dangerous. Clin Exp Pharmacol Physiol 1999; 26: 523-528.

33. Vargo D. L., Brater D. C., Rudy D. W., Swan S. K. Dopamine does not enhance furosemide - induced natriuresis in patioents with congestive heart failure. J Am Soc Nephrol 1996; 7: 1032-1037.

34. Welch W.J. Adenosine, type I receptors: role in proximal tubule Na+ reabsorption. Acta Physiol (Oxf) 2015; 213 (1): 242-248.

35. Sica D. A., Gehr T. W. Diuretic use in stage five chronic kidney disease and end - stage renal disease. Curr Opin Nephrol Hypertens 2003; 12: 483-490.

36. Bragg-Gresham J. L., Fissell R. B., Mason N. A. et al. Diuretic use, residual renal function, and mortality among hemodialysis patients in the Dialysis Outcomes and practice Pattern Study (DOPPS). Am J Kidney Dis 2007; 49: 426-431.

37. Stamatakis M. K. Treatment and prevention of acute renal failure. J Pharm Pract 2002; 15 (5): 392-404.

38. Brater D. C. Pharmacology of diuretics. AmJ Med Sci 2000; 319: 38-50.

39. Schetz M. Should we use diuretics in acute renal failure? Best practice & research. Clin Anaestheosiol 2004; 18 (1): 75-89.

40. Piccinni P., Gramaticopolo S. Diuretics in Intensive Care: Positive and Negative Aspects. In Allaria B., eds. Practical Issues in Anesthesia and Intensive Care. Milan: Springer-Verlag Italia; 2012: 59-71.

41. Bonegio R., Lieberthal W. Role of apoptosis in the pathogenesis of acute renal failure. Cur Opinion Nephrol Hypertens 2002; 11: 301-308.

42. Denton M. D., Chertow G. M., Brady H. R. “Renal dose" dopamine-for the treatment of acute renal failure: scientific rationale, experi-mentalstudies and clinical trials. Kidney Int 1996; 49: 1-4.

43. Mathur V. S., Swan S. K., Lambrecht L. J. et al. The effects of fenoldopam, a selective dopamine receptor agonist, on systemic and renal hemodynamics in normotensive subjects. Crit Care Med 1999; 27: 1832-1837.

44. Lewis J., Salem M. M., Chertow G. M. et al. Atrial natriuretic factor in oliguric acute renal failure. Am J Kidney Dis 2000; 36: 767-774.

45. Kellum J. A., Mehta R. L., Ronco C. Acute dialysis quality initiative (ADQI). Contrib Nephrol 2001; 132: 258-265.

46. Hull R. P., Goldsmith D. A. J. Nephrotic syndrome in adults. BMJ 2008; 336: 1185-1189.

47. Ghafari A.,Mehdizadeh A., Alavi-Darazam I. et al. Co-administration of Albumin-Furosemide in Patients with the Nephrotic Syndrome. Saudi J Kidney Dis Transpl 2011; 22 (3): 471-475.

48. Kodner C. Nephrotic Syndrome in Adults: Diagnosis and Management. Am Fam Physician 2009; 80 (10): 1129-1134.

49. Brater D. C. Diuretic therapy. N Engl J Med 1998; 339: 229-395.

50. Agarwal R., Gorski J., Sundblad K., Brater D. C. Urinary protein binding does not affect response to furosemide in patients with nephrotic syndrome. J Am Soc Nephrol 2000; 11: 1100-1105.

51. Esnault V. L., Erhlas A., Delcroix C., Moutel M. G., Nguyen J. M. Diuretic and enhanced sodium restriction results in improved anti-proteinuric response to RAS blocking agents. J Am Soc Nephrol 2005; 1 №5: 4-7 4-481.

52. Kunz R., Friedrich C., Wolbers M., Mann J. F. Meta-analysis: effect of monotherapy and combination therapy of renin-angiotensin system on proteinuria in renal diseases. Ann Intern Med 2008; 148: 30-48.